Inhibition of ERG Activity in Patient Derived Prostate Cancer Xenografts using the Small Molecule Inhibitor YK-4-279
Ontology highlight
ABSTRACT: ERG activity was blocked using YK-4-279 in three subcutaneously implanted ERG+ (LuCaP 23.1, 86.2, and 35) and one ERG- (LuCaP 96) PDX. Tumor volume (TV), body weight (BW), serum prostate specific antigen (PSA), and overall survival (OS) were compared to vehicle treated controls. Changes in gene expression were assessed by RNASeq and tissue microarrays were constructed to assess necrosis, proliferation, apoptosis, microvessel density, and ERG expression.
ORGANISM(S): Homo sapiens
PROVIDER: GSE86387 | GEO | 2017/11/16
SECONDARY ACCESSION(S): PRJNA341588
REPOSITORIES: GEO
ACCESS DATA